AbbVie's Skyrizi Approved in EU for Pediatric Plaque Psoriasis
The European Commission has approved AbbVie’s Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis in children and adolescents aged six years or older. This approval expands the drug’s use, potentially increasing its market reach.
Tickers: $ABBV